Lone Star Bio
Filter News
Found 15,001 articles
-
With the Thanksgiving holiday upon us, BioSpace felt it was important to give thanks for some of the positive things that have happened this year. And there are many!
-
Castle Biosciences Presents Data Reinforcing the Clinical Utility of Its DecisionDx® Dermatologic Portfolio
11/24/2021
Castle Biosciences, Inc. today announced oral presentations on its DecisionDx® gene expression profile (GEP) tests for skin cancer at the American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting, held Nov. 19-21, 2021.
-
Resonant to Participate in The Benchmark Company 10th Annual Discovery Conference on December 2, 2021
11/24/2021
Resonant Inc. (NASDAQ: RESN), a provider of radio frequency (RF) filter solutions developed on a robust intellectual property platform, designed to connect People and Things, today announced that management will participate in The Benchmark Company 10th Annual Discovery One-on-One Investor Conference.
-
InGeneron Publishes Significant Support for the Existence of Naturally Pluripotent Stem Cells in All Organs in the Adult Body
11/23/2021
InGeneron, Inc., a clinical stage regenerative medicine and cell therapy company, announced the publication of the first comprehensive analysis providing significant support for the existence of naturally pluripotent stem cells in all organs.
-
Lantern Pharma Announces Share Repurchase Program - Nov 22, 2021
11/22/2021
Lantern Pharma Inc., a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced that its board of directors has authorized a share repurchase program to acquire up to $7 million of the Company's common stock.
-
BioSpace Movers & Shakers, Nov. 19
11/19/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Data Demonstrating DecisionDx®-Melanoma Was a Significant, Independent Predictor of Metastatic Recurrence in Stage I-III Cutaneous Melanoma Published in Future Oncology
11/19/2021
Castle Biosciences, Inc. today announced the publication of a study of patients with stage I-III cutaneous melanoma.
-
Caris Life Sciences Announces Appointment of Lloyd B. Minor to Board of Directors
11/19/2021
Caris Life Sciences announced today the appointment of Lloyd B. Minor , M.D. to the Caris Board of Directors, effective immediately.
-
Natera's Panorama SMART Study Results Accepted for Publication by the American Journal of Obstetrics and Gynecology (AJOG)
11/19/2021
Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, announced that the first manuscript from the landmark SMART study has been accepted for publication by the American Journal of Obstetrics and Gynecology (AJOG).
-
Reata Pharmaceuticals Receives Fast Track Designation From the FDA for Omaveloxolone for the Treatment of Friedreich’s Ataxia
11/18/2021
Reata Pharmaceuticals, Inc. (Nasdaq: RETA), (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced the U.S. Food and Drug Administration (“FDA”) has granted Fast Track Designation for omaveloxolone for the treatment of Friedreich’s ataxia.
-
Molecular Templates, Inc. Announces Fast Track Designation Granted by FDA for MT-6402
11/18/2021
Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for MT-6402 for the treatment of patients with advanced non-small cell lung cancer (NSCLC) expressing PD-L1.
-
Plus Therapeutics Announces Positive Interim Data from ReSPECT™-GBM Phase 1 Clinical Trial at the 2021 Society for Neuro-Oncology Annual Meeting
11/18/2021
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today released positive interim data on its lead investigational drug, Rhenium-186 NanoLiposome (186RNL), from the first-in-man Phase 1 ReSPECT™-GBM clinical trial in patients with recurrent glioblastoma (GBM) at the 2021 Society for Neuro-Oncology Annual Meeting and Education Day being held in Boston, Massachusetts.
-
Marker Therapeutics Announces that Data from Investigator-Sponsored Phase 1 Study With its MultiTAA-Specific T Cells to be Presented at the 2021 American Society of Hematology Annual Meeting
11/18/2021
Marker Therapeutics, Inc. (NASDAQ: MRKR), today announced that data from a Phase 1 study investigating its MultiTAA-specific T cells were selected for oral presentation at the 2021 American Society of Hematology (ASH) Annual Meeting.
-
Caris Precision Oncology Alliance Announces the Addition of Columbia University Irving Medical Center to Its Collaborative Network of Precision Medicine Experts
11/18/2021
Caris Life Sciences® announced today that the Herbert Irving Comprehensive Cancer Center (HICCC) has joined Caris' Precision Oncology Alliance™ (POA).
-
Cassava Sciences Initiates a Second Phase 3 Study of Simufilam for the Treatment of Patients with Alzheimer’s Disease
11/18/2021
Cassava Sciences, Inc., a biotechnology company, announced it has initiated a second Phase 3 study of simufilam, the Company’s investigational drug for patients with Alzheimer’s disease.
-
Vaxxinity Announces Closing of IPO and Partial Exercise of Underwriters’ Option to Purchase Additional Shares
11/18/2021
Vaxxinity, Inc. announced the closing of its IPO of 6,000,000 shares of class A common stock at a public offering price of $13 per share on Nov 15, 2021 as well as the subsequent closing on Nov 18, 2021 of the issuance of an additional 537,711 shares of class A common stock, pursuant to a 30-day option granted to the underwriters to purchase up to an additional 900,000 shares of class A common stock at the initial public offering price, less underwriting discounts and commissions.
-
RADIOMEDIX AWARDED $2.0 M NCI SBIR DIRECT-TO-PHASE II GRANT TO DEVELOP DRUG FOR TARGETED ALPHA-EMITTER THERAPY
11/18/2021
RadioMedix, a clinical-stage biotechnology company developing radiotheranostic drugs, announced that it has been awarded a $2.0M Direct to Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute at the US National Institutes of Health.
-
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2021
11/18/2021
ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), today provided a corporate update and reported financial results for the fiscal year ended September 30, 2021.
-
Medicenna Receives Award for Excellence in Clinical Trials in Connection with an Upcoming Presentation at the 26th Annual Meeting of the Society for Neuro-Oncology
11/18/2021
Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), today announced that John H. Sampson, MD, PhD, MHSc, MBA, Robert H. and Gloria Wilkins Distinguished Professor of Neurosurgery at Duke University School of Medicine and member of Medicenna’s Board of Directors, received The Abstract Award for Excellence in Clinical Trials in connection with an upcoming oral presentation on MDNA55.
-
The U.S. Securities and Exchange Commission has launched an investigation into Texas-based Cassava Sciences.